🕵️ MAZE Therapeutics, Inc. ($MAZE)
SEC insider & ownership activity, last 12 months · CIK 1842295 · every row links its SEC filing
Over the last 12 months insiders sold $18.1M with no open-market buying against it. Bernstein Harold sold $7.6M through a 10b5-1 trading plan in 22 lots (Dec–Jul). 1 planned sale is pending, the largest $627K (Atul Dandekar). No red-flag 8-Ks in the window.
🚨 1 signal active —
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 6 sellers, $18.1M (64 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Bernstein Harold | 0 | – | 22 | $7.6M | Jul 1, 2026 |
| Dandekar Atul | 0 | – | 13 | $4.4M | Jun 29, 2026 |
| Jason V. Coloma | 0 | – | 13 | $2.8M | Jul 1, 2026 |
| Bachrodt Amy | 0 | – | 13 | $1.6M | Apr 1, 2026 |
| Catherine Sohn | 0 | – | 2 | $1.1M | Jan 7, 2026 |
| Richard H. Scheller | 0 | – | 1 | $464K | Sep 15, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| ARCH Venture Fund X Overage, L.P. | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| ARCH Venture Partners X, L.P. | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| ARCH Venture Partners X Overage, L.P. | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| ARCH Venture Partners X, LLC | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| Keith Crandell | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| Kristina Burow | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| Steven Gillis | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| Robert Nelsen | 9.4% | 13G | May 15, 2025 | filing ↗ | |
| Third Rock Ventures IV, L.P. | 9.3% | 13G | Feb 13, 2026 | filing ↗ | |
| Third Rock Ventures GP IV, L.P. | 9.3% | 13G | Feb 13, 2026 | filing ↗ | |
| TRV GP IV, LLC | 9.3% | 13G | Feb 13, 2026 | filing ↗ | |
| DEEP Track Capital, LP | 9.0% | 13G | Aug 14, 2025 | filing ↗ | |
| DEEP Track Biotechnology Master Fund, Ltd. | 9.0% | 13G | Aug 14, 2025 | filing ↗ | |
| David Kroin | 9.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Frazier Life Sciences Public Fund, L.P. | 9.0% | 13G | Feb 13, 2026 | filing ↗ | |
| Fhmlsp, L.P. | 9.0% | 13G | Feb 13, 2026 | filing ↗ | |
| Fhmlsp, L.L.C. | 9.0% | 13G | Feb 13, 2026 | filing ↗ | |
| Paradigm Biocapital Advisors LP | 6.1% | 13G | Apr 1, 2026 | filing ↗ | |
| Paradigm Biocapital Advisors GP LLC | 6.1% | 13G | Apr 1, 2026 | filing ↗ | |
| Senai Asefaw, M.D. | 6.1% | 13G | Apr 1, 2026 | filing ↗ | |
| Janus Henderson Group PLC | 5.8% | 13G | May 15, 2026 | filing ↗ | |
| David E. Goel | 5.7% | 13G | May 14, 2025 | filing ↗ | |
| Blackrock, Inc. | 5.4% | 13G | Jul 29, 2026 | filing ↗ | |
| Paradigm Biocapital International Fund Ltd. | 5.4% | 13G | Apr 1, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Atul Dandekar | $627K | Jul 29, 2026 | filing ↗ |
| Jason V. Coloma | $1.0M | Jul 1, 2026 | filing ↗ |
| Harold Bernstein | $1.4M | Jul 1, 2026 | filing ↗ |
| Jason V. Coloma | $908K | Jun 1, 2026 | filing ↗ |
| Jason V. Coloma | $895K | May 15, 2026 | filing ↗ |
| Atul Dandekar | $911K | Mar 30, 2026 | filing ↗ |
| Harold Bernstein | $3.4M | Mar 10, 2026 | filing ↗ |
| Sekar Kathiresan | $1.2M | Jan 16, 2026 | filing ↗ |
| Catherine Sohn | $1.1M | Jan 7, 2026 | filing ↗ |
| Catherine Sohn | $96K | Jan 6, 2026 | filing ↗ |
| Harold Bernstein | $4.4M | Dec 29, 2025 | filing ↗ |
| Atul P Dandekar | $3.7M | Dec 29, 2025 | filing ↗ |
| Sekar Kathiresan | $425K | Dec 4, 2025 | filing ↗ |
| Sekar Kathiresan | $985K | Nov 21, 2025 | filing ↗ |
| Richard Scheller | $464K | Sep 15, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Shareholder vote (5.07) | Jun 8, 2026 | filing ↗ |
| Officer/director changes (5.02) | May 18, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Other events (8.01) | Apr 21, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 21, 2026 | filing ↗ |
| Earnings (2.02) | Mar 24, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 24, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 24, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 24, 2026 | filing ↗ |
| Material agreement (1.01) | Feb 2, 2026 | filing ↗ |
| Agreement terminated (1.02) | Feb 2, 2026 | filing ↗ |
| New financial obligation (2.03) | Feb 2, 2026 | filing ↗ |
| Earnings (2.02) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 6, 2025 | filing ↗ |
| Material agreement (1.01) | Sep 10, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Sep 10, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 10, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 10, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 2, 2025 | filing ↗ |
| Earnings (2.02) | Aug 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 12, 2025 | filing ↗ |